UBS reiterates Buy on Cardinal Health stock, $260 price target

Fiscal 2026 EPS guidance was raised to >$10.00 (a $0.25 increase to the prior midpoint), and the stock has returned 53.9% over the past year. Multiple firms moved bullishly on the name — UBS reiterated Buy with a $260 target, Morgan Stanley raised its target to $245 (Overweight), Evercore ISI to $260 (Outperform) and Leerink Partners reiterated Outperform at $275 — while the shares trade near $207.73. Management flagged stronger H1 demand with expected softening in H2, noted discrete tax favorability to hit fiscal Q3, said rising oil costs are not expected to be material in FY26, and announced leadership moves including Patricia A. Hemingway Hall as board chair and Mary Scherer's planned Feb 2027 retirement.

Analysis

The recent positive flow into the company looks less like a pure operational inflection and more like a classic earnings-visibility re-rating that attracts quant and fundamental momentum funds. That creates a feedback loop where buy-side model upgrades and dealer delta-hedging on call activity can push the multiple higher over weeks-to-months even if core margins move only modestly. Expect the loudest alpha window to be 1–3 months post-upgrade as positioning and short-covering unwind, then a second, smaller move around discrete tax or cash-flow beats when real cash conversion data arrives.

Operationally, the business has structural insulation from commodity-driven shocks because transportation/fuel is a modest share of its margin stack; therefore, only sustained, outsized fuel inflation or freight disruptions would materially change EPS. The bigger medium-term margin levers are mix shift toward higher-margin services, working-capital normalization, and contract re-pricing with health systems — each can add or subtract several hundred basis points of operating margin over 12–24 months. Leadership turnover raises execution risk on these initiatives: a transition window of 6–18 months is the likeliest timeframe for any guidance drift.

Catalyst cadence to watch: 1) quarterly cash-flow and free-cash-flow conversion versus adjusted EPS (next 1–2 quarters), 2) any disclosure on contract renewal wins/losses and payor pricing (next 2–4 quarters), and 3) appointment of key finance/operational hires (6–12 months). The consensus upside appears compressed into near-term multiple expansion; if underlying organic demand softens, the rerating can reverse quickly, making defined-risk hedges sensible for new longs.

Key Decisions for Investors

• Paired trade (6–12 months): Long CAH 3–4% portfolio weight vs short MCK equal notional (or another large peer) - Rationale: capture re-rating and execution delta while hedging market beta. Risk management: stop the pair if spread narrows <50% of entry; target 15–25% relative outperformance.
• Directional long (3–9 months): Buy CAH outright at current levels with a 2–3% portfolio allocation - Rationale: monetize momentum from analyst-driven flows and structural working-capital tailwinds. Risk management: tight 10% stop; take profits at +30% or on any miss to cash-flow conversion versus EPS.
• Defined-risk hedge (3–6 months): Buy CAH 3–6 month put spread (buy 1 OTM put, sell lower strike deeper OTM) sized to protect 25–50% of the long exposure - Rationale: insures against earnings reversion from one-time tax/cash timing effects. Cost/benefit: preserves upside while capping hedge cost.
• Event-watch small trade (0–3 months): Sell short-dated call overwrites on a portion of a long position or sell 1–2% covered calls to monetize near-term volatility if IV spikes after upgrades - Rationale: harvest premium during the immediate post-upgrade gamma window. Risk: cap upside to strike; monitor for accelerating fundamental beats that warrant rolling.